CRH Medical Corp (NYSEARCA:CRHM) had its price target reduced by Canaccord Genuity from $8.00 to $5.00 in a research report issued to clients and investors on Friday. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price objective would indicate a potential upside of 104.08% from the stock’s current price.

CRHM has been the subject of several other reports. Zacks Investment Research lowered CRH Medical Corp from a “hold” rating to a “sell” rating in a research note on Tuesday, April 11th. CIBC lowered CRH Medical Corp from a “sector outperform” rating to a “sector perform” rating in a research note on Monday, July 17th. TD Securities lowered CRH Medical Corp from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Scotiabank lowered CRH Medical Corp from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 14th. Finally, Royal Bank Of Canada upgraded CRH Medical Corp from a “sector perform” rating to an “outperform” rating in a research note on Friday, July 21st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $8.13.

CRH Medical Corp (CRHM) traded down 14.04% during mid-day trading on Friday, reaching $2.45. The company’s stock had a trading volume of 293,681 shares. The company has a 50-day moving average price of $4.77 and a 200-day moving average price of $6.37. CRH Medical Corp has a 12-month low of $2.45 and a 12-month high of $9.25.

ILLEGAL ACTIVITY NOTICE: “Canaccord Genuity Cuts CRH Medical Corp (NYSEARCA:CRHM) Price Target to $5.00” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/06/canaccord-genuity-cuts-crh-medical-corp-nysearcacrhm-price-target-to-5-00.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Mawer Investment Management Ltd. raised its position in shares of CRH Medical Corp by 374.5% in the first quarter. Mawer Investment Management Ltd. now owns 3,817,951 shares of the company’s stock worth $55,335,000 after buying an additional 3,013,311 shares during the last quarter. O Shaughnessy Asset Management LLC raised its position in shares of CRH Medical Corp by 162.8% in the first quarter. O Shaughnessy Asset Management LLC now owns 2,584,531 shares of the company’s stock worth $21,065,000 after buying an additional 1,600,920 shares during the last quarter. Barometer Capital Management Inc. purchased a new position in shares of CRH Medical Corp during the first quarter worth $6,083,000. Morgan Stanley raised its position in shares of CRH Medical Corp by 102.7% in the first quarter. Morgan Stanley now owns 1,288,285 shares of the company’s stock worth $10,564,000 after buying an additional 652,737 shares during the last quarter. Finally, Pembroke Management LTD raised its position in shares of CRH Medical Corp by 48.4% in the second quarter. Pembroke Management LTD now owns 1,647,800 shares of the company’s stock worth $12,160,000 after buying an additional 537,200 shares during the last quarter.

About CRH Medical Corp

CRH Medical Corporation is a Canada-based healthcare products and services company. The Company focused on providing physicians with services and products for the treatment of gastrointestinal diseases. The Company also provides anesthesiology services to gastroenterologists in the United States through its subsidiaries.

Analyst Recommendations for CRH Medical Corp (NYSEARCA:CRHM)

Receive News & Ratings for CRH Medical Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical Corp and related companies with MarketBeat.com's FREE daily email newsletter.